Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at ...

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

In June, Moderna and Merck reported clinical trial follow-up results showing that their combination mRNA cancer vaccine and ...

Workforce expansion authorized after the 2024 Harlem outbreak remains incomplete, with 35 staff onboard versus a planned 56, leaving gaps in inspection and response throughput. A second lethal cluster ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

FDA approved a subcutaneous furosemide autoinjector with IV-equivalent exposure for edema in adults with HF or CKD, expanding the Furoscix franchise beyond the on-body infusor. Rapid administration ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and ...

FDA approved zidesamtinib for previously treated ROS1+ locally advanced/metastatic NSCLC, marking GSK’s entry into approved lung cancer therapeutics following acquisition of Nuvalent’s portfolio. ROS1 ...

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...